These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 38277735)

  • 1. Contingency management is associated with positive changes in attitudes and reductions in cannabis use even after discontinuation of incentives among non-treatment seeking youth.
    Cooke ME; Knoll SJ; Streck JM; Potter K; Lamberth E; Rychik N; Gilman JM; Evins AE; Schuster RM
    Drug Alcohol Depend; 2024 Mar; 256():111096. PubMed ID: 38277735
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Alcohol substitution during one month of cannabis abstinence among non-treatment seeking youth.
    Schuster RM; Potter K; Lamberth E; Rychik N; Hareli M; Allen S; Broos HC; Mustoe A; Gilman JM; Pachas G; Evins AE
    Prog Neuropsychopharmacol Biol Psychiatry; 2021 Apr; 107():110205. PubMed ID: 33309538
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Assessing changes in sleep across four weeks among adolescents randomized to incentivized cannabis abstinence.
    Baumer AM; Nestor BA; Potter K; Knoll S; Evins AE; Gilman J; Kossowsky J; Schuster RM
    Drug Alcohol Depend; 2023 Nov; 252():110989. PubMed ID: 37839357
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A contingency management method for 30-days abstinence in non-treatment seeking young adult cannabis users.
    Schuster RM; Hanly A; Gilman J; Budney A; Vandrey R; Evins AE
    Drug Alcohol Depend; 2016 Oct; 167():199-206. PubMed ID: 27590742
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Biological correlates of self-reported new and continued abstinence in cannabis cessation treatment clinical trials.
    Baker NL; Gray KM; Sherman BJ; Morella K; Sahlem GL; Wagner AM; McRae-Clark AL
    Drug Alcohol Depend; 2018 Jun; 187():270-277. PubMed ID: 29698894
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Urinary 11-nor-9-carboxy-tetrahydrocannabinol elimination in adolescent and young adult cannabis users during one month of sustained and biochemically-verified abstinence.
    Schuster RM; Potter K; Vandrey R; Hareli M; Gilman J; Schoenfeld D; Evins AE
    J Psychopharmacol; 2020 Feb; 34(2):197-210. PubMed ID: 31535597
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Psychosocial interventions for cannabis use disorder.
    Gates PJ; Sabioni P; Copeland J; Le Foll B; Gowing L
    Cochrane Database Syst Rev; 2016 May; 2016(5):CD005336. PubMed ID: 27149547
    [TBL] [Abstract][Full Text] [Related]  

  • 8. One Month of Cannabis Abstinence in Adolescents and Young Adults Is Associated With Improved Memory.
    Schuster RM; Gilman J; Schoenfeld D; Evenden J; Hareli M; Ulysse C; Nip E; Hanly A; Zhang H; Evins AE
    J Clin Psychiatry; 2018 Oct; 79(6):. PubMed ID: 30408351
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Assessment of Withdrawal, Mood, and Sleep Inventories After Monitored 3-Week Abstinence in Cannabis-Using Adolescents and Young Adults.
    Sullivan RM; Wallace AL; Stinson EA; Montoto KV; Kaiver CM; Wade NE; Lisdahl KM
    Cannabis Cannabinoid Res; 2022 Oct; 7(5):690-699. PubMed ID: 34678051
    [No Abstract]   [Full Text] [Related]  

  • 10. Development of Mobile Contingency Management for Cannabis Use Reduction.
    Beckham JC; Calhoun PS; Chen Z; Dennis MF; Kirby AC; Treis ET; Hertzberg JS; Hair LP; Mann AJ; Budney AJ; Kimbrel NA
    Behav Ther; 2024 Jan; 55(1):1-13. PubMed ID: 38216224
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A contingency management intervention to reduce cannabis use and time to relapse in early psychosis: the CIRCLE RCT.
    Johnson S; Rains LS; Marwaha S; Strang J; Craig T; Weaver T; McCrone P; King M; Fowler D; Pilling S; Marston L; Omar RZ; Craig M; Spencer J; Hinton M
    Health Technol Assess; 2019 Aug; 23(45):1-108. PubMed ID: 31460865
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Depressive symptoms and cannabis use in a placebo-controlled trial of N-Acetylcysteine for adult cannabis use disorder.
    Tomko RL; Baker NL; Hood CO; Gilmore AK; McClure EA; Squeglia LM; McRae-Clark AL; Sonne SC; Gray KM
    Psychopharmacology (Berl); 2020 Feb; 237(2):479-490. PubMed ID: 31712969
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Assessing Changes in Symptoms of Depression and Anxiety During Four Weeks of Cannabis Abstinence Among Adolescents.
    Cooke ME; Gilman JM; Lamberth E; Rychik N; Tervo-Clemmens B; Evins AE; Schuster RM
    Front Psychiatry; 2021; 12():689957. PubMed ID: 34276449
    [No Abstract]   [Full Text] [Related]  

  • 14. Dronabinol and lofexidine for cannabis use disorder: A randomized, double-blind, placebo-controlled trial.
    Levin FR; Mariani JJ; Pavlicova M; Brooks D; Glass A; Mahony A; Nunes EV; Bisaga A; Dakwar E; Carpenter KM; Sullivan MA; Choi JC
    Drug Alcohol Depend; 2016 Feb; 159():53-60. PubMed ID: 26711160
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A phase III multisite randomised controlled trial to compare the efficacy of cannabidiol to placebo in the treatment of cannabis use disorder: the CBD-CUD study protocol.
    Bhardwaj AK; Mills L; Doyle M; Sahid A; Montebello M; Monds L; Arunogiri S; Haber P; Lorenzetti V; Lubman DI; Malouf P; Harrod ME; Dunlop A; Freeman T; Lintzeris N
    BMC Psychiatry; 2024 Mar; 24(1):175. PubMed ID: 38433233
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Abstinence and reduced frequency of use are associated with improvements in quality of life among treatment-seekers with cannabis use disorder.
    Brezing CA; Choi CJ; Pavlicova M; Brooks D; Mahony AL; Mariani JJ; Levin FR
    Am J Addict; 2018 Mar; 27(2):101-107. PubMed ID: 29457671
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A Web-Based Self-Help Intervention With and Without Chat Counseling to Reduce Cannabis Use in Problematic Cannabis Users: Three-Arm Randomized Controlled Trial.
    Schaub MP; Wenger A; Berg O; Beck T; Stark L; Buehler E; Haug S
    J Med Internet Res; 2015 Oct; 17(10):e232. PubMed ID: 26462848
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Influence of tiagabine maintenance on cannabis effects and related behaviors in daily cannabis users.
    Wesley MJ; Westgate PM; Stoops WW; Kelly TH; Hays LR; Lile JA
    Exp Clin Psychopharmacol; 2018 Jun; 26(3):310-319. PubMed ID: 29863387
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treatment models for targeting tobacco use during treatment for cannabis use disorder: case series.
    Lee DC; Budney AJ; Brunette MF; Hughes JR; Etter JF; Stanger C
    Addict Behav; 2014 Aug; 39(8):1224-30. PubMed ID: 24813547
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Goal commitment predicts cannabis use for adolescents in treatment.
    Kaminer Y; Ohannessian CM; Burke RH
    Subst Abus; 2019; 40(4):496-500. PubMed ID: 30810498
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.